Bailey D G, Carruthers S G
Victoria Hospital, University of Western Ontario, London, Canada.
Clin Pharmacol Ther. 1991 Apr;49(4):370-6. doi: 10.1038/clpt.1991.43.
The interaction between verapamil and beta-blockers may involve negative chronotropic, inotropic, and dromotropic effects. Three randomized, double-blind, crossover trials evaluated standardized submaximal exercise hemodynamics after oral verapamil (120 mg) and beta-blocker, alone and in combination, in groups of eight healthy men. The beta-blockers were propranolol (80 mg), metoprolol (100 mg), and pindolol (5 mg). During submaximal exercise, each beta-blocker produced similar reductions in heart rate. Likewise, each verapamil and beta-blocker combination caused greater decreases in heart rate and prolongation of PR interval than did either drug alone. Only the verapamil and propranolol combination produced greater reduction of systolic blood pressure and prolongation of rate-adjusted PR interval. All verapamil and beta-blocker combinations caused frequent adverse events, predominantly exercise fatigue and resting first-degree heart block. Although the verapamil and metoprolol or pindolol combinations produced lesser negative dromotropic or inotropic effects compared with verapamil and propranolol, coadministration of verapamil and any beta-blocker should be performed cautiously.
维拉帕米与β受体阻滞剂之间的相互作用可能涉及负性变时、变力和变传导效应。三项随机、双盲、交叉试验评估了8名健康男性在口服维拉帕米(120毫克)和β受体阻滞剂单独及联合使用后标准化次极量运动时的血流动力学情况。β受体阻滞剂分别为普萘洛尔(80毫克)、美托洛尔(100毫克)和吲哚洛尔(5毫克)。在次极量运动期间,每种β受体阻滞剂均可使心率产生相似程度的降低。同样,维拉帕米与β受体阻滞剂的每种组合均比单独使用任一药物更能降低心率并延长PR间期。仅维拉帕米与普萘洛尔的组合能使收缩压有更大程度的降低,并使校正心率后的PR间期延长。所有维拉帕米与β受体阻滞剂的组合均导致频繁的不良事件,主要为运动疲劳和静息一度房室传导阻滞。尽管与维拉帕米和普萘洛尔相比,维拉帕米与美托洛尔或吲哚洛尔的组合产生的负性变传导或变力效应较小,但维拉帕米与任何β受体阻滞剂联合使用时仍应谨慎。